CONCLUSIONS
Finally, adopting MICi, a comprehensive concept, a new
PK/PD analysis approach for β-lactam/β-lactamase inhibitor combination
therapy was developed. In comparison to existing PK/PD parameters
(f T>CT), the PK/PD parameters
(f T>MICi) and their target values in
this newly designed PK/PD analysis approach were more practical,
generic, and accurate. PK/PD analysis employingf T>MICi might theoretically be used
in β-lactam/β-lactamase inhibitor combination therapy and
antimicrobial/antimicrobial combination therapy. Furthermore, this is
the first report of aztreonam/nacubactam being effective against
carbapenemase-producing K. pneumoniae , particularly NDM-producingK. pneumoniae . By improving the treatment of drug-resistant
bacterial infections, this study’s findings should help improve human
health and welfare.